Valchlor in the Treatment of Lichen Planopilaris
Summary
The primary objective of this study is to assess the potential effectiveness of once daily application of Valchlor in decreasing disease activity in patients with Lichen Planopilaris. The primary measurement of efficacy will be with the Lichen Planopilaris Activity Index (LPPAI) before and after 6 months of treatment. Secondary measures of efficacy will be the mean follicular density, Physician Global assessment (PGA) score, and the Dermatology Quality of Life Index (DQLI) score before and after six months of therapy.
Timeline
- Start
- 2018-04-01
- Primary completion
- 2019-08-30
- Completion
- 2019-08-30
Outcome
Met primary endpoint
registry MEDIAN Valchor Treatment of Lichen Planopilaris: Week 24: -66.7 (-100.0 to 66.7) percentage of change from baseline NCT03417141 ↗
registry analysis (superiority test); Valchor Treatment of Lichen Planopilaris; p = 0.006; Wilcoxon (Mann-Whitney) NCT03417141 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | mechlorethamine | Small molecule | 0.016 % | Topical |